InnoCare Pharma said its oral TYK2 inhibitor fadeucravacitinib met the primary endpoint in a Phase 3 trial for adults with moderate-to-severe plaque psoriasis. The company positioned the result as a major late-stage step for the drug, reinforcing interest in TYK2-targeted therapies that aim to control inflammatory signaling with differentiated safety profiles. Fadeucravacitinib’s Phase 3 success expands the competitive TYK2 landscape, where multiple next-generation agents are vying for labels in inflammatory dermatology. For InnoCare, the Phase 3 readout strengthens the case for subsequent regulatory interactions and the likelihood of continued development through late-stage planning. The company’s announcement provides a near-term validation signal for investors tracking the progression from clinical proof-of-concept into larger efficacy datasets. Next catalysts will include detailed outcomes beyond the primary endpoint, including key secondary endpoints and safety across the trial populations.